echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > ASCO-2021 Express: Harvard University: Breast Cancer Drugs Can Extend Progression-Free Survival of Glioblastoma

    ASCO-2021 Express: Harvard University: Breast Cancer Drugs Can Extend Progression-Free Survival of Glioblastoma

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In most glioblastomas, the cyclin D-CDK4/6-Rb pathway is activated.


    Breast cancer

    In order to effectively evaluate the potential impact of Abemaciclib on the overall survival (OS) of newly diagnosed glioblastoma, and at the same time to develop information about potential genomic biomarker associations, Abemaciclib is listed as an innovative glioblastoma therapy personalized A test group of the screening test (INSIGhT).


    diagnosis





    And explored the relationship between the efficacy of Abemaciclib and cyclin D-CDK4/6-Rb pathway genome changes.



    However, compared with the control group (median 15.


    The core conclusion of this RCT: Abemaciclib is well tolerated and prolongs PFS, but there is no evidence that compared with standard radiotherapy and chemotherapy, overall survival has improved.


    Abemaciclib is well tolerated and prolongs PFS, but there is no evidence that compared with standard radiotherapy and chemotherapy, overall survival has improved.







    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.